SBHMY - Week In Review: Vivo Raises $600 Million In First Tranche Of China PE Fund

• Vivo Capital, a US-China healthcare investor, held its first closing of a yuan-denominated private equity fund at $600 million, with a target of bringing the fund to $1.5 billion.
• SciNeuro Pharma, a Shanghai CNS company, acquired global rights to Lp-PLA2 inhibitors for neurodegenerative diseases from GlaxoSmithKline.
• Nanjing IASO Bio reported China accepted its IND for a BCMA CAR-T therapy, equecabtagene autoleucel, in patients with an autoimmune disease, Neuromyelitis Optica Spectrum Disorder.

For further details see: